Revance Therapeutics Inc. (NASDAQ:RVNC)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $12.61 and last traded at $12.91, with a volume of 98,708 shares trading hands. The stock had previously closed at $12.91.

Several equities analysts have commented on the stock. Brean Capital reiterated a “hold” rating on shares of Revance Therapeutics in a report on Thursday, June 23rd. SunTrust Banks Inc. decreased their price objective on shares of Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday, June 14th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $35.00 price objective (down from $54.00) on shares of Revance Therapeutics in a report on Tuesday, June 14th. Guggenheim reiterated a “buy” rating and issued a $55.00 price objective on shares of Revance Therapeutics in a report on Tuesday, June 14th. Finally, Zacks Investment Research downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $40.46.

The firm has a 50 day moving average of $16.62 and a 200-day moving average of $19.89. The stock’s market capitalization is $367.78 million.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.12. During the same period in the prior year, the firm earned ($0.65) EPS. Equities analysts expect that Revance Therapeutics Inc. will post ($3.53) EPS for the current fiscal year.

Other institutional investors recently modified their holdings of the company. Jennison Associates boosted its position in shares of Revance Therapeutics by 0.8% in the third quarter. Jennison Associates now owns 78,156 shares of the biopharmaceutical company’s stock valued at $2,326,000 after buying an additional 603 shares during the period. Principal Financial Group Inc. boosted its position in shares of Revance Therapeutics by 4.4% in the fourth quarter. Principal Financial Group Inc. now owns 81,748 shares of the biopharmaceutical company’s stock valued at $2,793,000 after buying an additional 3,481 shares during the period. California State Teachers Retirement System boosted its position in shares of Revance Therapeutics by 19.3% in the fourth quarter. California State Teachers Retirement System now owns 33,966 shares of the biopharmaceutical company’s stock valued at $1,160,000 after buying an additional 5,492 shares during the period. Columbus Circle Investors boosted its position in shares of Revance Therapeutics by 139.8% in the fourth quarter. Columbus Circle Investors now owns 61,295 shares of the biopharmaceutical company’s stock valued at $2,094,000 after buying an additional 35,734 shares during the period. Finally, Russell Frank Co bought a new position in shares of Revance Therapeutics during the fourth quarter valued at $1,384,000.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.